The mAChR family consists of five distinct subtypes, denoted M 1 to M 5 (and encoded by the genes CHRM1 to CHRM5). Three of these receptor subtypes (M 1 , M 3 and M 5 ) have been shown to couple to G proteins of the G q/11 family, whereas the remaining two subtypes (M 2 and M 4 ) preferentially signal through the G i/o family of G proteins 2 . The mAChRs have a central role in human physiology, regulating heart rate, smooth muscle contraction, glandular secretion and many fundamental functions of the central nervous system (CNS) 3 . Currently, drugs targeting muscarinic receptors are used for the treatment of several pathophysiological conditions, including chronic obstructive pulmonary disease, overactive bladder and Sjögren's syndrome 3 . Despite the powerful and diverse pharmacological actions of muscarinic receptor agonists and antagonists, the development of these drugs for other clinical applications has probably been held back, at least in part, by the lack of smallmolecule ligands that can inhibit or activate specific mAChRs with high selectivity. As a result, the precise physiological and pathophysiological roles of the individual mAChR subtypes have, until recently, remained poorly defined. However, during the past 15 years the generation and phenotypic analysis of Chrm1-to Chrm5-knockout mice has been instrumental in improving our understanding of the biology of the individual mAChRs 3 .
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Recent studies with novel mAChR mouse models have provided additional insights into the physiological roles of the different mAChR subtypes 4 . Moreover, during the past few years, several laboratories have succeeded in developing ligands that show high selectivity for specific mAChR subtypes 5, 6 . In contrast to conventional muscarinic receptor ligands, which bind to the orthosteric receptor site, most of these new ligands bind to distinct allosteric sites. Such allosteric ligands can influence the potency and efficacy of orthosteric ligands, and they may possess agonistic or inverse agonist activity in their own right. Interestingly, bitopic muscarinic receptor ligands with preference for certain subtypes have also been developed recently [7] [8] [9] . Such agents, which can interact with both allosteric and orthosteric receptor sites simultaneously, offer new opportunities to target specific mAChR subtypes for therapeutic purposes.
The recent determination of the first mAChR structures (M 2 and M 3 subtypes) represents a milestone in the mAChR field [10] [11] [12] . These studies have provided the first molecular views of mAChRs in both their inactive 10,11 and active conformations 12 , revealing the molecular nature of the binding sites for orthosteric muscarinic receptor ligands. Moreover, structural and computational studies have identified the mechanisms by which drug-like allosteric modulators bind to the M 2 subtype we emphasize the potential therapeutic implications of these novel findings. As mAChRs are prototypic class A GPCRs, the topics covered herein have implications for other members of this receptor superfamily.
Novel mAChR mouse models Since the late 1990s, studies with Chrm1-to Chrm5-knockout mice have elucidated many important physiological functions of the individual mAChR subtypes 3 . The outcome of this work suggested that modulating the activity of specific mAChR subtypes by selective ligands might prove to be beneficial for the treatment of many CNS disorders and other clinical conditions 3 . Until recently, essentially all phenotyping studies were carried out with conventional, constitutive mAChRknockout mice, which lack one or more of the genes encoding mAChRs throughout development in all cells of the body. The proper interpretation of the phenotypes observed with conventional mAChR-knockout mice is often complicated because individual mAChR subtypes are expressed in many different tissues and cell types, and compensatory molecular or physiological changes can occur during development.
To circumvent these difficulties, novel conditional knockout mice have been created that lack specific mAChR subtypes only in certain tissues or cell types. For these studies, mice containing 'floxed' versions of specific genes encoding mAChRs were crossed with transgenic mice expressing Cre recombinase in a cell type-or tissue-selective fashion (TABLE 1) . mAChR knock-in mice have also been reported, in which the native genes encoding M 3 or M 4 receptors -CHRM3 or CHRM4, respectively-were replaced with mutant versions (TABLE 1) . Here, we summarize several recent studies that have used novel mAChR-mutant mice as well as conventional mAChR-knockout mice. These studies are discussed in the context of selected human diseases in which the development of novel classes of drugs targeting muscarinic receptors might be beneficial.
Targeting mAChRs in disease
Alzheimer's disease. Alzheimer's disease, which is the most common form of dementia, is recognized as a major public health crisis 14 . At present, there are no drugs available that are highly effective in preventing Alzheimer's disease or slowing its progress. Based on behavioural, pharmacological, anatomical and neurochemical evidence, M 1 receptor-selective agonists seem to have the potential to ameliorate the symptoms of Alzheimer's disease and related cognitive disorders 15 . In fact, several recent studies support the concept that M 1 receptorselective agonists or positive allosteric modulators (PAMs) may prove to be useful as cognition-enhancing drugs. Davis et al. 16 demonstrated that M 1 receptor deficiency increases amyloidogenic processing of amyloid precursor protein (APP) -a key feature of Alzheimer's disease -in a mouse model of Alzheimer's disease. In a related study, Medeiros et al. 17 reported that the lack of M 1 receptors further exacerbated cognitive processes and Alzheimer's disease-related pathological features in a mouse model of Alzheimer's disease. In addition, Chrm1-knockout mice exhibited an age-dependent cognitive decline in tasks that they performed normally at a younger age 17 . Most importantly, several recent studies have shown that compounds that act as PAMs at M 1 receptors have cognition-enhancing activity in rodents and are able to improve impaired cognition in mouse models of Alzheimer's disease 18, 19 . Taken together, these new findings provide a rational basis for the development of M 1 -selective drugs (PAMs or agents that can activate M 1 receptors directly) for the treatment of Alzheimer's disease and related disorders.
Schizophrenia. Schizophrenia, which is a chronic disabling brain disorder that affects ~1% of the general population 20 , is characterized by enhanced central dopaminergic signalling. Studies with conventional mAChRknockout mice have indicated that the lack of central M 1 and/or M 4 receptors leads to a 'dopamine hypersensitivity phenotype' , which suggests that agents that can enhance signalling through these receptor subtypes may be endowed with antipsychotic activity 3 30, 31 . These effects were greatly reduced or abolished in Chrm1-knockout mice or in mice that were deficient in both M 1 and M 4 receptors (Chrm1 -/-
Chrm4
-/-mice). Moreover, Schmidt et al. 32 reported that the reinforcing effects of chronic cocaine selfadministration are significantly increased in Chrm4-knockout mice. These findings indicate that centrally active drugs that can selectively stimulate M 1 and/or M 4 receptors may prove to be useful in the treatment of drug addiction. Type 2 diabetes. Type 2 diabetes has emerged as a major threat to public health worldwide 33 . One of the key pathophysiological features of type 2 diabetes is that pancreatic β-cells are unable to secrete sufficient insulin to overcome peripheral insulin resistance. Studies with β-cell-selective Chrm3-mutant mice 34, 35 showed that strategies aimed at enhancing the activity of β-cell M 3 receptors may prove to be useful for the treatment of type 2 diabetes. To further test this hypothesis, two recent studies 36,37 analysed transgenic mice that expressed an M 3 receptor-based designer receptor (G q DREADD; where DREADD stands for 'designer receptor exclusively activated by a designer drug') selectively in pancreatic β-cells. This modified M 3 receptor is unable to bind acetylcholine, the endogenous ligand, but can be selectivity activated by clozapine N-oxide (CNO), a drug that is otherwise pharmacologically inert 36, 38 . Systematic metabolic analysis of this mouse line confirmed that CNO-dependent activation of this designer M 3 receptor has numerous beneficial effects on β-cell function and is able to prevent experimentally induced diabetes 36, 37 . Although there is evidence that the ability of β-cell M 3 receptors to promote insulin release depends on the presence of G proteins of the G q family 39 , two recent studies suggest that M 3 receptor-mediated activation of arrestin-dependent β-cell pathways may further enhance insulin secretion 40, 41 . Currently, ligands that are able to selectively promote signalling through M 3 receptors are not available, and the development of such agents would greatly facilitate studies aimed at testing the potential usefulness of targeting β-cell M 3 receptors for the treatment of type 2 diabetes and related metabolic disorders.
Cancer. Accumulating evidence suggests that mAChRdependent signalling pathways can promote cell proliferation and cancer progression 42, 43 . Interestingly, Raufman et al. 44 demonstrated that Chrm3-knockout mice displayed reduced epithelial cell proliferation, tumour number and size in a mouse model of colon neoplasia (azoxymethane-induced colon cancer). In a related study 45 , M 3 receptor deficiency was associated with a pronounced reduction in tumour number and volume in a genetic model of intestinal neoplasia (Apc Min/+ mice). Magnon et al. 46 reported that M 1 receptor deficiency inhibited mAChR-mediated prostate cancer invasion and metastasis in two mouse models of prostate cancer. These findings support the concept that subtype-selective mAChR antagonists may prove to be clinically useful for the treatment of certain forms of cancer. Novel mAChR pharmacology A major shift in drug discovery has been the recognition that most -if not all -GPCRs possess spatially distinct allosteric sites that can be exploited by small molecules to modulate the activity of orthosteric ligands 6, 47, 48 . The mAChRs are arguably the pre-eminent models for contributing to our understanding of GPCR allostery 5, [49] [50] [51] (see BOX 1 for a representative list of muscarinic allosteric modulators).
Pharmacological characteristics of allosteric modulators.
Allosteric ligands promote conformational changes in the receptor that manifest as an alteration in the properties of a ligand bound to the classical, orthosteric site, and by the potential for direct activation of receptor signalling via the allosteric site 52 . PAMs enhance orthosteric activity, negative allosteric modulators (NAMs) inhibit it, and agents that occupy an allosteric site but do not change the activity of orthosteric ligands are referred to as neutral allosteric ligands (NALs). Allosteric compounds that directly activate GPCRs are called allosteric agonists. However, these designations are contextual, as they are dependent on the receptor, orthosteric ligand and the assay system used [52] [53] [54] . For example, the M 1 receptorselective modulator BQCA (REF. 55 ) acts solely as a PAM of acetylcholine activity when assayed in a cell line with low M 1 receptor expression 56 and/or at signalling pathways that are weakly coupled to the M 1 receptor 57 , but it acts as both a full allosteric agonist and as a PAM in a system with a high M 1 receptor reserve 57 . Characteristically, the effects of allosteric modulators are saturable: that is, no further activity is observed above a certain limit, irrespective of modulator dose. This phenomenon is driven by the cooperativity between orthosteric and allosteric sites, and can range from subtle fine-tuning to very large modulation. For instance, N-chloromethyl brucine potentiates acetylcholine affinity by threefold at the M 3 receptor 58 , whereas BQCA potentiates acetylcholine affinity at the M 1 receptor by ~100-fold 57 . A second property is probe dependence 59 , whereby the magnitude and direction of the allosteric effect mediated by the same modulator acting at the same receptor varies depending on the orthosteric ligand used to probe receptor function. A striking example is LY2033298, which is a PAM of oxotremorine-M signalling at the M 2 receptor, but a NAM of xanomeline at the same receptor 60 . The third characteristic of GPCR allostery is biased agonism, which refers to the ability of different ligands to stabilize a subset of functionally relevant GPCR conformations such that different signalling outputs are achieved at the exclusion of others 54, 61, 62 . Biased agonism can be imposed on the signalling of orthosteric agonists by co-bound modulators. One example is the compound VU0029767, which potentiates acetylcholine-mediated phospholipase C activity via the M 1 receptor, but does not affect acetylcholine-induced phospholipase D activation 63 . Finally, a crucial property of allosteric modulators is potential mAChR-subtype selectivity. This can be attained either by targeting a less conserved site on the receptor or via selective cooperativity with the orthosteric ligand, even if the allosteric site is shared between subtypes 64 . Indeed, selective cooperativity is the major mechanism by which compounds such as thiochrome and LY2033298 show high selectivity for the M 4 receptor [64] [65] [66] .
Bitopic muscarinic ligands. In recent years, research has turned to the rational design of hybrid molecules, which are designed to simultaneously bridge orthosteric and allosteric sites within a single receptor; such compounds have been termed 'bitopic' , 'dualsteric' or 'multivalent' 7, 67, 68 . As summarized in FIG. 1 , each of the different modes of targeting mAChRs has its pros and cons. The orthosteric site can provide high affinity and is
Box 1 | Selected allosteric modulators of mAChRs
The allosteric modulators listed here have been used to provide important insights into muscarinic acetylcholine receptor (mAChR) allostery. Note that this list is by no means exhaustive. Some of the modulators bind to all five mAChR subtypes but are listed under the mAChR subtype for which they have been most extensively studied. supported by decades of studies of structure-activity relationships (SARs), but mAChR-subtype selectivity remains largely unattainable. Allosteric sites provide the opportunity to achieve greater receptor selectivity and promote more physiological response patterns. However, high-affinity modulators have not been reported to date, and certain modulator scaffoldslike many orthosteric drugs -show minimal improvements in activity despite numerous modifications 69 . The bitopic ligand approach attempts to target the allosteric site to achieve selectivity and the orthosteric site to provide high affinity.
Despite some challenges 7, 68, 70 , the pursuit of bitopic ligands has yielded interesting pharmacological findings. Disingrini et al. 71 were the first to combine a nonselective, high-affinity orthosteric agonist (iperoxo) with an M 2 receptor-selective allosteric modulator to generate an M 2 receptor-selective agonist. This concept was extended by Mohr and colleagues [72] [73] [74] . Interestingly, although bitopic agonists with mAChR-subtype selectivity and signalling bias have been described, substantial gains in affinity were generally not observed 7 . By contrast, the bitopic muscarinic receptor antagonist THRX-160209 demonstrated remarkable gains in both affinity and selectivity for the M 2 receptor 75 , which highlights that the appropriate combination of an orthosteric antagonist, NAM and linker can yield ligands with the desired pharmacological properties.
These findings raise the possibility that previously described selective and/or biased agonists may represent unappreciated bitopic ligands. Consistent with this concept, a study of the biased M 2 receptor partial agonist McN-A-343 unmasked a pure orthosteric agonist and pure NAM of agonist efficacy following reverse engineering of McN-A-343 into fragments 76 . A more recent study of the M 1 receptor-selective agonist TBPB also identified orthosteric and allosteric fragments of this molecule 53 . This latter study is of particular relevance because TBPB, together with other novel M 1 receptorselective agonists such as AC-42 and 77-LH-28-1, was originally classified as an allosteric agonist [77] [78] [79] [80] . However, like McN-A-343, these agents display mixed modes of orthosteric or allosteric pharmacology depending on the experimental assay conditions 48, 53, 81 . It is thus likely that such compounds adopt novel poses within the mAChRs that bridge both orthosteric and allosteric sites, hence accounting for their unique pharmacology 81 .
Towards the molecular mechanisms of allostery. The simplest mechanism to account for allosteric behaviour is the Monod-Wyman-Changeux (MWC) model 82, 83 , which postulates that receptors exist in an equilibrium between different states, and that orthosteric and allosteric ligands select one or more of these states over others 84 . Because this occurs via topographically distinct sites, the state that is stabilized by one class of ligand can present a modified binding surface for the other class, which is manifested as the allosteric interaction. If this mechanism were restricted to two states, it would be expected that any ligand favouring the active state would display some degree of agonism, whereas compounds stabilizing the inactive state would show some degree of inverse agonism. Moreover, allosteric ligands that favoured the active state would be PAMs for agonists but NAMs for inverse agonists; this is the simplest molecular explanation for probe dependence. Interestingly, these predictions were confirmed in a recent study of BQCA activity at the M 1 receptor 57 , which indicates that some mAChR modulators can mediate their effects predominantly through a simple conformational selection mechanism.
However, this simple model does not explain the probe dependence observed with compounds such as LY2033298 at the M 2 receptor, which can show PAM or NAM activity with different agonists 60 . It also does not explain biased allosteric modulation, or why compounds such as gallamine are NAMs for agonists and antagonists 85 . Thus, additional mechanisms seem to be involved, most obviously involving multiple active receptor states 86 . Prior studies have also shown that compounds such as staurosporine and WIN62577 interact with a second allosteric site on mAChRs that is distinct from the common site 87, 88 . The location of this site remains unidentified, but it may be intracellular 89 . If so, one can envisage more complex scenarios that involve an allosteric mechanism with respect to the orthosteric site, but potentially a steric mechanism with respect to receptor-transducer interactions. Similarly, it has been postulated that gallamine may utilize a two-step binding process, involving a peripheral domain that is distinct from the common allosteric site, in its interaction with the receptor 85 . Finally, the simplest allosteric models do not explicitly incorporate receptor oligomers as the key functional units; a tetrameric arrangement has been proposed, at least for the M 2 receptor, to account for the observed cooperative effects of both orthosteric and 90, 91 . Thus, despite the identification of a vast repertoire of behaviours for muscarinic allosteric ligands, the molecular mechanisms underlying these behaviours are only starting to be elucidated. It is particularly exciting, therefore, that recent structural and computational biology breakthroughs have shed new light on this matter.
Structural insights into ligand binding mode.
Although mAChRs are among the most extensively studied GPCRs in terms of their pharmacology and biological function, the molecular structures of these receptors have, until recently, remained poorly understood. In 2012 the first mAChR structures were published 10,11 , revealing the molecular organization of the M 2 and M 3 receptor subtypes in inactive, antagonist (inverse agonist)-bound conformations. This work was made possible owing to advances in GPCR biochemistry and crystallography, principal among them the T4 lysozyme fusion method 92 , new detergents 93 , the lipidic cubic phase crystallization method 94, 95 and micro-focus X-ray diffraction data collection 96 . The structures of the M 2 and M 3 receptors revealed that, like other biogenic amine receptors, members of the mAChR family share the seven-pass transmembrane topology and overall fold of other GPCRs, with a few features extending outside of the membrane plane (FIG. 2) . The ligand-binding pocket is deeply buried within the membrane (FIGS 2,3a) , and is situated similarly to the orthosteric binding sites of the related histamine 97 , dopamine 98 , adrenaline [99] [100] [101] and serotonin 102, 103 receptors. The ligands bound to the M 2 and M 3 receptors in the two crystal structures -quinuclidinyl benzilate (QNB) and tiotropium, respectively -are both antagonists (inverse agonists) with similar chemical structures. In each case, the ligand occupies a similar pose (FIG. 3b) , engaging in extensive hydrophobic contact with the receptor. A smaller number of polar contacts are evident: a pair of hydrogen bonds between Asn 6.52 and the ligand hydroxyl and ketone, and a charge-charge interaction between the cationic amine of the ligand and the conserved Asp 3.32 (superscripts denote Ballesteros-Weinstein 104 GPCR numbering) (FIG. 3b) . The latter interaction is seen in all biogenic amine receptor structures solved to date and has been shown to make a major energetic contribution to binding 105 . The paired hydrogen bonding between the ligand and Asn 6.52 seems to be a unique feature of the mAChR family and has been proposed to be an important factor in slow ligand dissociation from mAChRs 106 .
Comparison of the orthosteric ligand-binding pockets of the M 2 and M 3 receptors reveals a probable underlying factor for the limited success in the development of mAChR-subtype-selective ligands. The residues lining the orthosteric binding site are conserved absolutely in sequence and, moreover, are positioned almost identically in space in both receptors (FIG. 3b) . Although there are a few subtle differences between the structures of the M 2 and M 3 receptors, attempts to exploit these minor structural variations to obtain ligands with increased mAChR-subtype selectivity have thus far been unsuccessful 105 . Strikingly, in the structures of the M 2 and M 3 receptors, the orthosteric ligand is almost completely occluded from solvent, with a tyrosine 'lid' located directly above -that is, extracellular to -the ligand (FIG. 3) . This lid divides a large, solvent-accessible cavity into two distinct regions, only one of which interacts with the bound antagonists (FIG. 3a) . The upper portion of this cavity, termed the extracellular vestibule, is lined with residues that have been implicated in the binding of allosteric modulators 107 . As discussed below, LY2119620, which is a PAM of mAChRs, binds to this outer cavity 12 . Although the backbone fold of the structures surrounding this allosteric site is remarkably well conserved between the M 2 and M 3 receptors, the amino acid side chains lining it show more divergence 10 . Hence, the development of ligands that interact with non-conserved amino acids in the allosteric site provides a possible means by which subtype-selective therapeutics might be developed.
Molecular dynamics studies of the M 3 receptor indicate that the allosteric site may have a role in facilitating the binding of orthosteric ligands. Simulations of tiotropium binding to the M 3 receptor suggested that this ligand may rapidly interact with the extracellular vestibule of the receptor, but in these simulations tiotropium failed to enter the orthosteric site 10 . This may be due to limitations in the timescale accessible to molecular dynamics simulations, as well as the slow binding kinetics of tiotropium 10 . Notably, it has been shown experimentally that orthosteric ligands can bind to an allosteric site on the M 2 receptor, albeit with low affinity 90 . Interactions with the extracellular vestibule may initiate desolvation of the ligand, which is required for the occupation of the orthosteric pocket. If binding to the allosteric site is indeed a metastable state for orthosteric muscarinic ligands, deliberate exploitation of this feature could potentially facilitate the development of muscarinic ligands with increased mAChR-subtype selectivity and/or improved kinetic properties.
Molecular basis for NAM function at the M 2 receptor.
Recently, the molecular mechanism of allosteric modulator binding to the inactive state of the M 2 receptor was investigated by computational molecular dynamics and site-directed mutagenesis studies 13 . Using the inactive crystal structure of the M 2 receptor as a starting model, the binding of a series of structurally diverse cationic small-molecule modulators was simulated using long-timescale molecular dynamics. These simulations suggested that modulator binding to the extracellular vestibule may be driven largely by interactions between cationic amines on the modulators and aromatic residues on the receptor. The allosteric pocket appears to contain two cation-π centres: one including Trp422 7.35 and Tyr177 ECL2 (extracellular loop 2), and the other bounded by Tyr80 2.61 and Tyr83 2.64 . The importance of these regions in modulator binding was confirmed by site-directed mutagenesis experiments, which showed that affinity for the NAM heptane-1,7-bis(dimethyl-3'-phthalimidopropyl)ammonium bromide (C 7 /3-phth) could be enhanced by the addition of more aromatic residues or acidic residues to the extracellular vestibule 13 . Dror et al. 13 also examined the interaction between the modulators and orthosteric antagonists to obtain insights into cooperativity. Two key mechanisms were proposed. The first was electrostatic repulsion between the modulator and the antagonist. The second was conformational coupling between orthosteric and allosteric sites. Specifically, molecular dynamics simulations indicated that bulky modulators (for example, alcuronium) are likely to stabilize an open extracellular vestibule conformation reminiscent of that seen in the crystal structure of the M 2 receptor bound to QNB 11 . By contrast, smaller modulators (for example, C 7 /3-phth) may preferentially stabilize a closed conformation of the extracellular vestibule 13 , similar to that seen in molecular dynamics simulations of the unliganded M 3 receptor 10 . Thus, in the inactive state the smaller modulators generally exhibit negative cooperativity with antagonists (that is, they destabilize antagonist binding), whereas the bulkier modulators typically enhance antagonist binding. Consistent with this model, the addition of bulky substituents to C 7 /3-phth improved the binding of this NAM to the M 2 receptors occupied by radiolabelled . Taken together, these data support the concept that orthosteric antagonist binding can be enhanced or diminished by a modulator that preferentially stabilizes a particular conformation of the extracellular vestibule.
Activation and positive allosteric modulation of the M 2 receptor. The initial structures of the M 2 and M 3 receptors were obtained in complex with high-affinity antagonists (inverse agonists) and consequently represent inactive receptor conformations. Obtaining crystals of active GPCRs has thus far proved to be extremely challenging; this is probably due in large part to the conformational heterogeneity induced by agonist binding 108 . To date, these problems have been surmounted in the case of rhodopsin [109] [110] [111] , the β 2 -adrenergic receptor (β 2 -AR) 112, 113 and, more recently, the M 2 receptor 12 . In the last two cases, the first active-state structures have been obtained with the aid of conformationally selective antibody fragments, which mimic G proteins and stabilize the active conformation of the receptors to which they bind. This approach should prove to be useful for obtaining active-state structures of other GPCRs in the future.
The most striking feature of the active-state M 2 receptor structure, like that of active β 2 -AR and rhodopsin, is the outward rotation of transmembrane domain 6 to create a G protein-binding cavity on the intracellular surface of the receptor (FIG. 4a,b) . The active-state structure of the M 2 receptor shows substantial similarity to the active states of both β 2 -AR and rhodopsin, with a slightly closer resemblance to the latter structure.
One of the most intriguing structural features of active β 2 -AR and rhodopsin is that both receptors show far more subtle rearrangements in the ligand-binding pocket and extracellular surface than on the intracellular side. This observation suggests that these regions are relatively fixed conformationally, with few changes associated with agonist binding or activation. By contrast, the active structure of the M 2 receptor revealed large changes throughout the receptor, including an unexpected contraction of the extracellular vestibule, in addition to changes on the surface of the intracellular receptor that closely parallel those seen in β 2 -AR and rhodopsin (FIG. 4c,d ). This extracellular rearrangement results in a narrower allosteric site and a smaller orthosteric site that is occluded entirely from solvent (FIG. 4d) . The much smaller size of the orthosteric site is reflected by the lower molecular weight of muscarinic agonists compared to antagonists and inverse agonists.
In the active state of the M 2 receptor, the small orthosteric agonist iperoxo engages Asp103 3.32 with its cationic head group, whereas the polar isoxazoline tail contacts Asn404 6.52 with a single hydrogen bond, paralleling the interactions of the inactive receptor with the antagonist QNB (FIG. 4c) . These two interactions are bridged by an acetylene moiety in iperoxo, which runs perpendicular to transmembrane domain 3. Within the binding site, iperoxo exhibits a high degree of shape complementarity to the active conformation, filling the pocket almost entirely (FIG. 4d) . By contrast, in the inactive conformation the M 2 receptor presents a large orthosteric site that is better suited to the binding of larger antagonists and inverse agonists. The exceptional complementarity of iperoxo with the active -but not inactive -orthosteric site of the receptor may account for its agonistic activity.
In addition to the substantial contraction of the orthosteric site upon activation, the extracellular vestibule is similarly much smaller in the active conformation of the M 2 receptor, even in the absence of a bound allosteric modulator. Isomorphous crystals were grown in the presence of LY2119620, a PAM of mAChRs 12 , and inspection of electron density maps revealed binding of this ligand to the extracellular vestibule (FIG. 4d) . Strikingly, structures of the active M 2 receptor with and without LY2119620 were highly similar, even in the extracellular vestibule 12 . Indeed, the only substantial change in this pocket was a reorientation of Trp422 7.35 , which directly interacts with the bound LY2119620. In addition, Phe181
ECL2 was poorly resolved in the allosteric complex, which suggests that this residue may become more mobile upon binding of the receptor to this modulator. As Phe181 ECL2 is a leucine residue in all other mAChR subtypes, interaction with this residue may allow modulators to have different effects on M 2 receptors compared to other mAChR subtypes.
The remarkable similarity of the extracellular vestibule conformation in the active M 2 receptor with and without bound LY2119620 suggests a mechanism for allosteric modulation. PAMs may achieve their effects by preferentially binding to and stabilizing the closed (that is, active) conformation of the extracellular vestibule.
In doing so, PAMs may shift the receptor conformational equilibrium towards active conformations not only of the allosteric site but also of the receptor as a whole (FIG. 5) . Analogously, NAMs may preferentially bind the open conformation of the extracellular vestibule seen in the inactive structures, thereby skewing the conformational ensemble of the receptor in favour of inactive states. In total, the mAChRs contain at least three binding sites that have been defined pharmacologically and structurally: the extracellular vestibule, the orthosteric binding pocket and the G protein-binding site (FIG. 5) .
Comparison of the active-and inactive-state structures of the M 2 receptor shows that all three sites can undergo substantial conformational rearrangements upon receptor activation. However, it is important to recognize that the crystal structures present only static views of a single receptor conformation and thus provide, at best, an incomplete picture.
The structures solved to date are suggestive of a concerted conformational change throughout all three sites, but it remains to be seen whether changes in each site can occur independently of one another. Such a possibility is suggested by structures of the A 2A adenosine receptor bound to agonists 114, 115 . Conformational changes in the orthosteric site are indicative of receptor activation, but the intracellular surface remains in a closed, inactive state. Activation of the mAChRs might similarly involve separable conformational changes at each of the three sites rather than a single concerted activation throughout the entire receptor. Spectroscopic and other biophysical assays will probably be required to definitively establish the mechanism of receptor activation and the means through which ligands stabilize active receptor conformations.
Conclusions and future challenges
The past few years have witnessed unprecedented progress in our understanding of the biology, pharmacology and structure of mAChRs. The use of novel mutant mouse models, including mAChR knock-in mice with altered signalling properties and mutant mice in which distinct mAChR subtypes can be deleted in a temporally and spatially controlled fashion, should provide more detailed insights into mAChR biology.
From a structural point of view, the most obvious future goal is to obtain high-resolution structures for all five mAChR subtypes, both in their inactive and active conformations, as well as in complex with different classes of ligands (orthosteric, allosteric or bitopic ligands). Such studies may reveal a broad spectrum of mAChR conformations depending on the receptor subtype and activation state, as well as receptor-bound ligands. Identifying the structural basis that underlies the ability of mAChRs, as well as other GPCRs, to interact with G proteins, arrestins, GPCR kinases (GRKs) and other GPCR-associated signalling molecules should also be of great general interest. Taken together, the outcome of these studies should considerably facilitate the development of novel muscarinic receptor agents and tools that show a high degree of mAChR subtype selectivity and hopefully cause fewer side effects. Finally, lessons learned from work in the mAChR field may be applicable to GPCRs in general, offering new insights into how to design better therapeutic agents targeting this important class of cell surface receptors.
